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Utilization of Sterol Carrier Protein-2 by
Phytanoyl-CoA 2-Hydroxylase in the Peroxisomal
 Oxidation of Phytanic Acid
cation mechanism. Defects in the -oxidation pathway
can result in a spectrum of neurological syndromes in
humans, including Adult Refsum’s Disease (ARD).
Symptoms of ARD include deterioration of vision due
to retinitis pigmentosa followed by blindness, anosmia,
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South Parks Road deafness, peripheral neuropathy, ataxia, ichthyosis, and
skeletal dysplasias, with premature death eventually oc-Oxford OX1 3QY
United Kingdom curring due to cardiac arrhythmias. The only available
treatment for ARD involves reduction of dietary phytanic2 Department of Chemical Pathology
King’s, Guy’s & St. Thomas’ Medical School acid, which ameliorates some symptoms (e.g., ataxia,
ichthyosis), but visual or olfactory damage appear to beSt. Thomas’ Hospital Campus
Lambeth Palace Road irreversible [2, 5].
The individual steps of the -oxidation pathway haveLondon SE1 7EH
United Kingdom only recently been elucidated. Initially, phytanic acid is
converted to its coenzyme A ester by a nonspecific3 The Department of Pharmacy & Pharmacology
The University of Bath ligase [6]. Phytanoyl-CoA (1) is then 2-hydroxylated in
a reaction catalyzed by an iron(II) and 2-oxoglutarate-Claverton Down
Bath BA2 7AY dependent oxygenase, phytanoyl-CoA 2-hydroxylase
(PAHX) [7–10]. A thiamine pyrophosphate-dependent ly-United Kingdom
ase cleaves 2-hydroxyphytanoyl-CoA into pristanal [11,
12] and formyl-CoA [13]. Pristanal is converted to pris-
tanic acid by an NADPH-dependent oxidoreductaseSummary
[14]. Reesterification with coenzyme A by LCFA-CoA
synthetase [15] or very-long-chain fatty-acyl-CoA syn-Since it possesses a 3-methyl group, phytanic acid is
thetase [16] to give pristanoyl-CoA (2) and epimerizationdegraded by a peroxisomal -oxidation pathway, the
[17, 18] allows further degradation by the “normal”first step of which is catalyzed by phytanoyl-CoA
-oxidation pathway [3]. Like all other characterized per-2-hydroxylase (PAHX). Mutations in human PAHX
oxisomal proteins, the enzymes in the -oxidation path-cause phytanic acid accumulations leading to Adult
way are initially synthesized with N- or C-terminal peroxi-Refsum’s Disease (ARD), which is also observed in a
somal targeting sequences (PTS-1 [19, 20] or PTS-2 [21])sterol carrier protein 2 (SCP-2)-deficient mouse model.
that are required for importation into peroxisomes.Phytanoyl-CoA is efficiently 2-hydroxylated by PAHX in
In ARD around 45% of cases are associated withvitro in the presence of mature SCP-2. Other straight-
defects in phytanoyl-CoA 2-hydroxylase (PAHX) [7, 9,chain fatty acyl-CoA esters were also 2-hydroxylated
22, 23], with the remainder associated with defects inand the products isolated and characterized. Use of
peroxisomal protein import via peroxin 7 [24, 25]. PAHXSCP-2 increases discrimination between straight-
may also be implicated both in aspects of signal trans-chain (e.g., hexadecanoyl-CoA) and branched-chain
duction [26] and blood coagulation [27]. The biochemi-(e.g., phytanoyl-CoA) substrates by PAHX. The results
cal effects of some clinically observed mutations ofexplain the phytanic acid accumulation in the SCP-2-
PAHX can be rationalized on the basis of primary se-deficient mouse model and suggest that some of the
quence comparisons, secondary structure predictions,common symptoms of ARD and other peroxisomal
and active site motifs apparent from the crystal struc-diseases may arise in part due to defects in SCP-2
tures of bacterial oxygenases [4].function caused by increased phytanic acid levels.
Naturally occurring phytanoyl-CoA (1) exists as a mix-
ture of its (3S)- and (3R)-epimers, both of which are
Introduction substrates for PAHX [4, 28]. Only one of the two possible
diastereoisomers is formed by PAHX-catalyzed oxida-
Phytanic acid is a branched-chain isoprenoid fatty acid tion of either the (3S)- or (3R)-epimer [29]. In vivo sub-
derived from chlorophyll and is part of the human diet. It strate analog studies [30] suggest that the absolute
cannot be degraded by the normal fatty acid -oxidation stereochemistry of the diastereomeric 2-hydroxyphy-
pathway due to the presence of a 3-methyl group, and tanoyl-CoA products formed from the (3R)- and (3S)-
instead a preliminary -oxidation pathway within peroxi- epimers is (2S, 3R) and (2R, 3S), respectively. 2-oxoglu-
somes excises its C-2 methylene group to give pristanic tarate-dependent oxygenases are believed to catalyze
acid [1, 2]. This can be further degraded by the -oxida- prime substrate oxidation via a ferryl [Fe(IV)O/Fe(III)-
tion pathway, initially in peroxisomes and subsequently O·] intermediate in a radical rebound process [31]. We
in mitochondria [3]. The enzymes of the -oxidation considered it improbable that a PAHX-phytanoyl-CoA
pathway [4] are found in many different types of organ- (1) binding mode with a rigid three-point attachment of
isms, suggesting that it is an important general detoxifi- coenzyme A, methyl group, and fatty side chain could
lead to the observed stereoselectivity. Thus, we pro-
posed that PAHX binds its phytanoyl-CoA substrate by4 Correspondence: m.d.lloyd@bath.ac.uk
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the 3-methyl group and either the coenzyme A or fatty
side chain [28].
Phytanoyl-CoA (1) is amphipathic and forms micelles
in aqueous environments; hence,  cyclodextrin has
been used as a solubilizing agent during previous in
vitro experiments with PAHX [8]. In humans, phytanic
acid is transported in lipoproteins, with most being
found associated with cholesterol in low-density lipo-
protein (LDL) [32]. We considered the possibility that
the isoprenoid side chain of phytanoyl-CoA (1) either
binds to the peroxisomal membrane or is solubilized by
a coprotein during the in vivo reaction catalyzed by
PAHX. A precedent for the latter possibility is seen in
retinoid metabolism, were biological activity is mediated
via complexes with cellular retinoid binding proteins
[33]. A human acyl-CoA binding protein (ACBP) has been
reported [34], but it is apparently localized in the cytosol.
Although ACBP selectively binds acyl-CoA esters, there
is no reported evidence for its presence in the perox-
isome.
Sterol carrier protein 2 (SCP-2) is located within the
peroxisome and is involved in  oxidation of fatty acyl-
CoA esters [35, 36]. SCP-2-deficient mice accumulate
phytanic acid [37] and have a similar phenotype in some
respects to ARD with the presence of neuropathy, hypo-
lipidaemia, and cardiac arrhythmias when fed a diet
containing phytanic acid. However, they lack certain key
features of human ARD including retinitis pigmentosa,
anosmia, ataxia, ichthyosis, and deafness [2, 36]. How-
ever, in this case it cannot be completely excluded that
phytanic acid accumulation arises as a consequence of
secondary defects in SCPx (3-ketoacyl-CoA thiolase/
SCP-2) function in  oxidation [37]. Phytanoyl-CoA (1)
Figure 1. Kinetic Analyses of PAHX-Catalyzed Conversion of Phyta-is known to bind much more tightly to SCP-2 (Kd  250
noyl-CoAnM) than phytanic acid, pristanic acid, or pristanoyl-
(Top) In the presence of mature SCP-2 and (bottom) in the presenceCoA (2) [37]. In addition, binding of phytanoyl-CoA (1)
of  cyclodextrin. Note that at high substrate concentrations into SCP-2 reduces the rate of its hydrolysis to phytanic
(bottom graph), the rate of reaction is reduced (noncompetativeacid [38]. We therefore considered the possibility that
substrate inhibition) compared to that expected, leading to nonline-
SCP-2 is a solubilizing protein for substrates of the arity in the double reciprocal plot (inset).
-oxidation pathway. Here we demonstrate that SCP-2
acts as a solubilizing coprotein during the in vitro PAHX-
assays. (3R, 3S)-phytanoyl-CoA conversion was stimu-catalyzed reaction and propose an analogous in vivo
lated by the presence of mature SCP-2 compared to therole for SCP-2.
level observed with  cyclodextrin [4, 28], the previously
used in vitro solubilizing agent. The identity of the epi-
Results and Discussion meric 2-hydroxyphytanoyl-CoA product obtained in the
presence of SCP-2 was confirmed by coelution of the
Expression and Purification of Sterol Carrier product peak with authentic product upon HPLC analy-
Protein 2 sis and ESI MS analysis. The reaction apparently dis-
The pro- and mature forms of human SCP-2 were cloned played Michaelis-Menten kinetics in the presence of
and expressed in E. coli at 20% of total cell protein. SCP-2 (Figure 1, top), and the following apparent steady-
A convenient large-scale protein purification procedure state parameters were derived: KM  29.5  1.7 M;employing cation-exchange chromatography was de- Kcat  0.40  0.01 s1; Kcat/KM  1.34  104 M1 s1.veloped, giving protein at 99% purity (by SDS-PAGE). Product formation was linear over a 10 min time course
The identity of mature SCP-2 was confirmed by ESI in the presence of SCP-2. In contrast, non-Michaelis-
MS (13,242 Da calculated; 13,243  0.96 Da observed). Menten kinetics were observed in the presence of 
Recombinant mature PAHX was obtained at 95% pu- cyclodextrin, and apparent KM values for phytanoyl-CoArity (by SDS-PAGE) as previously described [4]. varied between 7 and 39 M. At higher phytanoyl-CoA
(1) concentrations, apparent noncompetitive substrate
inhibition occurred in the presence of  cyclodextrinHydroxylation of Phytanoyl-CoA
The activity of highly purified mature PAHX was analyzed (Figure 1, bottom, inset). It is unclear what is the basis
of the observed inhibition, but it may be due to improperfor both 2-oxoglutarate conversion [39] and oxidative
modification of phytanoyl-CoA (1) [28] by separate solubilization. No reduction of activity at higher sub-
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Figure 2. Stimulation of 2-Oxoglutarate Con-
version by Straight-Chain Acyl-CoA Esters as
a Function of Chain Length
Levels of conversion are normalized to that
observed for phytanoyl-CoA in the presence
of  cyclodextrin (100%, 18.06 nmol/min/mg)
under standard assay conditions (final sub-
strate concentration in assay  50 M). A
10% conversion level was observed for
PAHX in the absence of any “prime” substrate
(“uncoupled turnover”). A chain length of zero
corresponds to coenzyme A, a chain length
of 2 corresponds to acetyl-CoA, etc. Results
of incubations are without addition of a solu-
bilizing factor (blue), with  cyclodextrin (red),
or with SCP-2 (yellow). Product formation (if
any) was observed by HPLC analyses for all
acyl-CoA esters that gave significant stimula-
tion of 2-oxoglutarate conversion (C-4 to C-
10 without solubilizing agent and C-12 to C-
18 with  cyclodextrin/SCP-2).
strate concentrations was observed when SCP-2 was the absence of SCP-2 or cyclodextrin. Acyl-CoA esters
with chain lengths longer than C-10 were not analyzedused as the solubilizing agent (Figure 1, top).
in the absence of solubilizing agents due to their insolu-
bility in aqueous solvents.Hydroxylation of Straight-Chain Fatty
Acyl-CoA Esters In the presence of  cyclodextrin, phytanoyl-CoA (1)
was converted to 2-hydroxyphytanoyl-CoA [4, 28].Some iron(II) and 2-oxoglutarate-dependent oxygen-
ases have been shown to accept a number of different Straight-chain acyl-CoA esters with side chains of 12–18
carbons stimulated 2-oxoglutarate conversion (Figureprime substrates, and the choice of substrate can deter-
mine the type of oxidative reaction performed [10]. 2) in the presence of  cyclodextrin, and 2-hydroxyl
product formation was observed by HPLC analysis.2-oxoglutarate-dependent oxygenases that have been
shown to convert unnatural substrates including proline In contrast to previous negative reports using whole
or permabilized hepatocytes [30, 45], hexadecanoyl-hydroxylase [40], DAOCS [41], DAOC/DAC synthase
[42], and CAS [43]. Little work has been reported on CoA (C-16 4) was converted in vitro via PAHX catalysis.
1H NMR and ESI MS analyses confirmed the structurethe substrate selectivity of PAHX, although 3-methyl-
hexadecanoic acid (probably as its CoA ester 3) is hy- of the product as 2-hydroxyhexadecanoyl-CoA. Kinetic
analysis of hexadecanoyl-CoA in the presence of SCP-2droxylated by permabilized cells [30, 44], presumably in
a PAHX-mediated process. We therefore investigated (Figure 3, top) gave the following apparent kinetic pa-
rameters: KM  25.1  1 M; Kcat  0.044  0.0005whether PAHX was able to hydroxylate straight-chain
fatty acyl-CoA esters by assaying for 2-oxoglutarate s1; Kcat /KM  1.75  103 M1 s1. In the presence of 
cyclodextrin, the apparent KM value varied between 40conversion (Figure 2) and acyl-CoA 2-hydroxylation (or
other oxidative modification) by HPLC (data not shown). and 50 M, and the kinetics approximated a Michaelis-
Menten curve (Figure 3, bottom). Thus, the in vitro cata-Three conditions were investigated: without any solubi-
lizing agent, in the presence of  cyclodextrin, and in lytic efficiency (as measured by Kcat/KM) of PAHX in the
presence of SCP-2 for hexadecanoyl-CoA (4) is approxi-the presence of SCP-2.
In the absence of any solublizing agent, there was no mately eight times less than for phytanoyl-CoA (1), with
a lower Kcat value accounting for the majority of theevidence for conversion of phytanoyl-CoA (1) within the
limits of detection for the HPLC assay, although some difference. A V/K competitive experiment using equimo-
lar quantities of phytanoyl-CoA (1) and hexadecanoyl-(uncoupled) 2-oxoglutarate conversion was observed
(Figure 2, far left). However, some straight-chain acyl- CoA (4) in the presence of SCP-2 confirmed the more
efficient conversion of phytanoyl-CoA (1) compared toCoA esters (C-4 to C-8) stimulated 2-oxoglutarate con-
version and were efficiently hydroxylated as judged by hexadecanoyl-CoA (4), with significant conversion of the
latter only being observed after the former was almostHPLC analysis. The minimum chain length for activity
under standard assay conditions appears to be four completely converted (Figure 4).
Heptadecanoyl-CoA (C-17) and arachidoyl-CoAcarbons, as no hydroxylation was observed with propio-
nyl-CoA (C-3) or acetyl-CoA (C-2). Decanoyl-CoA (C-20) were also converted to the anticipated 2-hydrox-
ylated products (as judged by HPLC and ESI MS analy-showed considerably reduced 2-oxoglutarate conver-
sion compared to octanoyl-CoA, and this probably re- ses). These observations demonstrate that PAHX does
not discriminate between substrates with an even orflects the reduced solubility of the former substrate in
Chemistry & Biology
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Figure 4. Comparison of the Efficiency of Conversion of Phytanoyl-
CoA (1) and Hexadecanoyl-CoA (3) by PAHX
Approximately 0.56 g were used per assay. Two experiments were
performed using a (1:1) mixture of (1) and (3) (50 M of each) in the
presence of mature SCP-2 [(1) red and (3) cyan] and  cyclodextrin
[(1) pink and (3) blue], respectively. Product formation was followed
by stopped HPLC assays of mixtures incubated for the required
length of time.
(Figure 5). Isovaleryl-CoA (5) was converted to the ex-
pected 2-hydroxylated product (Figure 5), the identity
of which was confirmed by 1H NMR and ESI-MS analy-
ses. This substrate displayed non-Michaelis-Menten ki-
netics, although the reason for this is unclear. PAHX-
mediated oxidation of isovaleryl-CoA was reduced by
the presence of SCP-2 in the standard assay conditions,
as judged by conversion of 2-oxoglutarate to succinate
Figure 3. Kinetic Analyses of PAHX-Catalyzed Conversion of Hexa- and CO2. This result contrasts with the effect of SCP-2
decanoyl-CoA on conversion of the long-chain fatty acyl-CoA deriva-
(A) In the presence of mature SCP-2 and (B) in the presence of  tives and is consistent with its role as a solubilizing
cyclodextrin. agent. Conversion of isovaleryl-CoA is probably reduced
in the presence of SCP-2 because the latter impedes
access of the former to the active site of PAHX. This
odd number of methylene groups and that some acyl- result also suggests that SCP-2 is not behaving as an
CoA esters with extended side chains can be hydrox- allosteric activator. PAHX is probably not important in
ylated. amino acid metabolism, even though isovaleryl-CoA (5)
Preferential metabolism of hexadecanoyl-CoA (4) by may be present in peroxisomes as a product of leucine
the -oxidation pathway (which is estimated to be 10–15 metabolism [47], as phytanoyl-CoA (1) is likely to be a
times greater than the rate of  oxidation [46]), together preferential substrate.
with observed substrate selectivity, may account for the In contrast to isovaleryl-CoA (5), isobutanoyl-CoA (6)
previous reports that hexadecanoyl-CoA (4) was not an was not found to be a substrate for PAHX (Figure 5). This
in vivo substrate for PAHX [30, 44]. Thus, peroxisomal result is consistent with the exclusion of pristanic acid
 oxidation of straight-chain fatty acids may only occur from the -oxidation pathway due to the presence of a
to a significant extent when phytanic acid intake in the
-methyl group. The importance of the -methylene group
diet is relatively low. However, it is possible that in vivo is also illustrated by the observation that 2-methylhexa-
behavior could be considerably different, depending on decanoyl-CoA (7) was not a substrate for PAHX [44].
the effect of the peroxisomal membrane or other pro-
teins on the behavior of the acyl-CoA substrates and
proteins. Metabolism of Unsaturated Substrates
Certain 2-oxoglutarate-dependent oxygenases can oxi-
dize unsaturated substrate analogs to epoxides [40–42].Hydroxylation of Branched Short-Chain Fatty
Acyl-CoA Esters Thus, commercially available trans-3-methyl-2-buten-
oyl-CoA (8) was assessed as a substrate for PAHX.We reasoned that if there was a methyl but not an (ex-
tended) fatty side-chain binding site within the enzyme, 2-oxoglutarate conversion was stimulated by its pres-
ence (Figure 6), but no oxidized product was observed.then PAHX may accept branched short-chained acyl-
CoA esters as substrates. Thus, several branched-chain Analogous uncoupling of prime substrate oxidation from
2-oxoglutarate conversion has been observed for sub-acyl-CoA esters were tested as substrates for PAHX
SCP-2 Complexes as PAHX Substrates
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Figure 5. Stimulation of 2-Oxoglutarate Con-
version by Branched-Chain Acyl-CoA Esters
Levels of conversion are normalized to that
observed for phytanoyl-CoA in the presence
of  cyclodextrin (100%, 18.06 nmol/min/mg)
under standard assay conditions (final sub-
strate concentration in assay 50 M). A 5%
conversion level was observed for PAHX in
the absence of any prime substrate. Condi-
tions shown are without solubilization agent
(blue), with  cyclodextrin (red), or with SCP-2
(yellow). A 2-hydroxylated product was ob-
served only when using isovaleryl-CoA as a
substrate. There was no evidence for oxidized
product formation with trans-3-methyl-2-
butenoyl-CoA or isobutanoyl-CoA. Incuba-
tion of phytanoyl-CoA did not give any prod-
uct in the absence of  cyclodextrin or SCP-2.
N/D indicates not determined.
strate analogs with other 2-oxoglutarate-dependent ox- noyl-CoA. Although phytanoyl-CoA (1) can be obtained
by chemical [28] or enzymatic [51] synthesis, its amphi-ygenases [48, 49].
The results suggest that other , -unsaturated fatty pathic properties make it difficult to handle. Diagnostic
assays using commercially available alternative sub-acids, e.g., phytenic acid, may not be directly metabo-
lized by the-oxidation pathway. They might be discrim- strates (Figure 6), such as hexadecanoyl-CoA (4) or iso-
valeryl-CoA (5), are therefore potentially useful. The for-inated against as substrates for PAHX because of the
constraints imposed by the geometry of the double mer requires solubilization, and so the latter is
potentially a better candidate for diagnostic assays. Inbond. Further, the anticipated epoxide products are po-
tential alkylating agents and are rare in nature. Sub- diagnostic assays, the possibility that PAHX mutations
[4] will affect conversion of substrate analogs differentlystrates with remote double bonds are known to bind
tightly to SCP-2 [50], but it is unclear if they can be to phytanoyl-CoA (1) must be considered, since differen-
tial effects of mutations on the oxidation of natural andmetabolized by the -oxidation pathway.
unnatural substrates has been observed for related oxy-
genases [52].Applications of Substrate Selectivity of PAHX
The results demonstrate that wild-type mature PAHX
can accept a number of alternative substrates to phyta- Biological Implications
The demonstration that PAHX can catalyze the hydroxyl-
ation of straight-chain fatty acyl-CoA esters, together
with the demonstration of a functional role for SCP-2
in both  and  fatty acid oxidation pathways raises
questions about how various metabolites are channeled
into the appropriate pathways. While discrimination be-
tween 3-methyl and 2-methyl substrates can be rela-
tively easily explained, it is less easy to explain how
metabolism of straight-chain fatty acyl-CoA esters (e.g.,
very-long-chain fatty acids) is regulated, since the in
vitro results suggest they can be processed by either
- or -oxidation pathways. The results suggest that
discrimination may be in part mediated by interactions
between SCP-2 and the enzymes involved. The pres-
ence of SCP-2 conjugates (e.g., SCPx [53]) physically
linking the coprotein and associated -oxidation en-
zyme (e.g., 3-ketoacyl-CoA thiolase) may make this pro-
cess more efficient. It is also possible that the enzymes
of both andoxidation are organized into multienzyme
complexes, and the overall structures and relationships
of these complexes may contribute to channeling of
intermediates into the appropriate pathways.
The -methylacyl-CoA “racemase” (Figure 7), which
catalyzes epimerization of (2R)-pristanoyl-CoA into (2S)-
pristanoyl-CoA [54], also links the - and -oxidation
pathways. Epimerization is also required subsequent to
Figure 6. Acyl-CoA Esters Tested as Substrates for PAHX the involvement of PAHX, in the -oxidation pathway,
to further metabolize the phytanoyl-CoA-derived inter-Enclosed compounds are those tested as substrates in this work.
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dence suggested that SCP-2 could be the small protein
binding factor, the most compelling being the bio-
chemical changes and some symptoms typical of ARD
observed in the SCP-2-deficient mouse model [37].
The in vitro results suggest that the in vivo substrates
for PAHX (and by extrapolation all other enzymes of
the -oxidation pathway) may be SCP-2 complexes.
Abnormal elevation of phytanic acid is diagnostic of
ARD (and some other peroxisomal disorders), but the
mechanisms by which the clinical symptoms are mani-
fested are unclear. The results in this paper suggest
that some of the common symptoms may result from
a functional reduction in the amount of SCP-2 due to
excessive accumulation of a ligand, e.g., phytanic acid
in ARD or (2R)-pristanic acid in -methylacyl-CoA ra-
cemase deficiency [54]. Direct binding of phytanic (or
pristanic) acid to alternative proteins, activation of per-
oxisomal proliferation elements [57], and direct toxic
actions effects may also be important. Indeed, phy-
tanic acid has been shown to activate the PPAR rece-
ptor in SCP-2-deficient mice [58], and upregulation
and binding of phytanic acid to liver fatty acid binding
protein has been demonstrated [59]. Understanding
the roles of these effects in disease pathology and
the development of symptoms is essential if effective
treatments for these disorders are to be achieved.
Experimental Procedures
Chemicals
All chemicals were supplied by the Sigma-Aldrich Chemical Co.
Figure 7. Proposed Involvement of SCP-2 in the Peroxisomal  and (Poole, Dorset, UK), unless otherwise stated, and were of analytical
 Oxidation of Phytanic and Pristanic Acids grade or higher. Fatty acyl-CoA esters were purchased from Larodan
Phytanoyl-CoA may be imported from the cytosol into the peroxi- Lipids (Malmo¨, Sweden). (3R,S, 7R, 11R)-phytanoyl-CoA was syn-
some as the SCP-2 complex (as shown) followed by further metabo- thesized as previously reported [28]. Chromatography systems and
lism. However, the possibility that the SCP-2 complex is formed columns were obtained from Amersham Biosciences (Little Chal-
subsequent to phytanoyl-CoA importation into the peroxisome can- font, Bucks., UK) or Bio-Rad (Hemel Hempstead, Herts., UK). Protein
not be excluded. Release of the chain-shortened acyl-CoA/carnitine purification was performed on an FPLC Bio-pilot system. CM-Seph-
ester from SCP-2 is anticipated upon export to mitochondria. It has arose was packed into a XK50/20 column (5  10 cm, 200 ml).
been suggested that pristanic acid is converted to pristanoyl-CoA Recombinant mature PAHX was purified to 95% purity (by SDS-
by long-chain fatty acyl-CoA synthetase [15] or very-long-chain fatty PAGE analysis) as previously described [4]. HPLC columns were
acyl-CoA synthetase [16]. Abbreviations: LCFA-CoA synthetase, obtained from Phenomenex (Macclesfield, Cheshire, UK). Oligonu-
long-chain fatty-acyl-CoA synthetase; PAHX, phytanoyl-CoA cleotides were obtained from Sigma-Genosys. Other molecular biol-
2-hydroxylase; 2HPCL, 2-hydroxyphytanoyl-CoA lyase; PDH, prista- ogy reagents were obtained from Stratagene (Amsterdam Zuidoost,
nal dehydrogenase; AMACR, -methylacyl-CoA racemase. The Netherlands) or New England Biolabs Ltd. (Hitchen, Herts., UK).
Cloning and Expression of SCP-2
The pro-SCP-2 gene was amplified from the IMAGE clone 1872828mediates with R-methyl groups originally at C-7 and
(http://image.llnl.gov) using the following primers: forward 5	-GAATC-11 of phytanic acid. It seems plausible that SCP-2 (or
TCCATATGGGTTTTCCGGAAGCC-3	; reverse 5	-GGATCCAAGCTits conjugates) is required for activity of all the enzymes
TTCAGAGCTTAGCGTTGCC-3	. Mature SCP-2 was amplified using
of the -oxidation pathway and -methylacyl-CoA “ra- the forward primer 5	-GAATTCCATATGAGCTCTGCAAGTGATGG-
cemase,” as well as those in the -oxidation pathway 3	 and the same reverse primer as before. Amplification products
[54]. It is also possible that peroxisomal metabolism were cloned into the pGEM-T vector and sequenced. The required
fragments were subcloned into the pET-24a vector using the 5	 Ndeof fatty acids is terminated at about the level of C-11
1 and 3	 Hind III restriction sites. Clones were expressed in E. coli(dimethylnonanoyl-CoA) (Figure 7) [3], because at this
BL21 (DE3) by induction with 0.5 mM IPTG for 4 hr. Both pro- andpoint fatty acids (and their coenzyme A esters) become
mature SCP-2 were expressed as 20% of the total cell protein.
significantly soluble in an aqueous environment, and Large-scale growths of recombinant E. coli clones were carried out
binding to SCP-2 is reduced [55, 56]. as previously described for PAHX [4].
Purification of SCP-2Significance
All manipulations were performed on ice or at 4
C. Fractions were
analyzed by SDS-PAGE using 15% (w/v) resolving and 3% (w/v)Consideration of the characteristics of phytanoyl-CoA
stacking gels. Protein concentrations were determined by the
(1) and the stereochemical aspects of the PAHX reac- method of Bradford [60]. Iso-electric points of pro- and mature
tion led to the proposal that the in vivo substrate for SCP-2 were determined with a Bio-Rad analytical flat bed IEF using
precast PhastGelTM IEF 3-9 gels (Amersham Biosciences). The mo-PAHX was a protein complex. Several pieces of evi-
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lecular weight of mature SCP-2 was determined by ESI MS (13,242 absence of  cyclodextrin or mature SCP-2. An efficient (95%)
conversion of substrate was observed (as judged by HPLC) underDa calculated; 13,243  0.96 Da observed).
Cells expressing mature SCP-2 (E. coli BL21(DE3)/pET24a, 10 g) standard assay conditions. 2-hydroxyisovaleryl-CoA was isolated
by HPLC (ODS [250 4.6 mm], 0.6 ml/min,   254 nm). The columnwere thawed and resuspended in 500 ml of 20 mM MOPS-NaOH,
10% (v/v) glycerol (pH 7.2), 1 mM benzamidine-HCl, 1 mM PMSF, was eluted with 30 mM NH4H2PO4, 10% (v/v) acetonitrile (pH 5.5),
for 10 min followed by a gradient to 15 mM NH4H2PO4, and 60% (v/v)0.5 mM 1,10-o-phenanthroline, and 2 mM DTT. After 15 min stirring,
the solution was sonicated for 5  30 s, power 5 with 60 s cooling acetonitrile (pH 5.5), over 5 min and 10 min at 60% (v/v) acetonitrile.
Retention times were 10.0 and 17.0 min for product and substrate,(W-380 sonicator, Utrasonic). DNA was precipitated with 1% (w/v)
streptomycin sulfate and 0.1% (w/v) PEI. After 10 min stirring, the respectively. The sample for ESI MS analysis was repurified using
NH4HCO3 as eluent: 1H NMR (500 MHz; D2O) (coenzyme A moiety)sample was centrifuged (JA-14 rotor, 12000 rpm, 22,000  g, 10
min) and loaded onto a CM-sepharose column equilibrated in the  0.6 (s, 3H, 2		-Me); 0.75 (s, 3H, 2		-Me); 2.30 (t, J  6.5 Hz, 2H,
2			-CH2); 2.90 (t, J  6.5 Hz, 2H, 2				-CH2); 3.20 (t, J  6.5 Hz, 2H,above buffer containing 0.1 mM 1,10-o-phenanthroline. The column
was washed with 1000 ml buffer, and protein was eluted with a 1				-CH2); 3.35 (t, J  6.5 Hz, 2H, 1			-CH2); 3.40 (m, 1H, 1 of 1		-
CH2); 3.70 (m, 1H, 1 of 1		-CH2); 3.90 (s, 1H, 3		-CH); 4.10 (br s, 2H,0–700 mM NaCl gradient over 900 ml with 25 ml fractions collected.
5	-CH); 4.45 (s, 1H, 4	-CH); 4.60 (2H, 2	-CH and 3	-CH under HODFractions 12–18 (330–505 mM NaCl) were pooled and concentrated
suppression); 6.15 (d, J  7 Hz, 1H, 1	-CH); 8.1 (s, 1H, 8-CH); 8.4in 300 and 50 ml Amicon stirred cells using YM-10 membranes.
(s, 1H, 2-CH); (isovaleryl moiety)  0.7 (d, J  7.0 Hz, 3H, Me); 0.8Purified SCP-2 was exchanged into 10 mM Tris-HCl, 10% (v/v) glyc-
(d, J  7.0 Hz, 3H, Me); 2.05–2.15 (m, 1H, (Me)2CH); 3.95 (d, J  4.0erol (pH 7.5) with an Econo-pak column (Bio-Rad), concentrated to
Hz, 1H, CHOHCOS). A COSY 1H NMR spectrum was consistent with10 mg/ml and stored at 80
C.
the assigned structure; m/z (-ve ESI MS)  867.27  0.23 (M); calc.
866.7 (M).Enzyme Assays and Kinetic Analysis
Incubations with octanoyl-CoA (1.2 mg) were carried out in theAssays were performed essentially as previously described [4], in
absence of  cyclodextrin or mature SCP-2. An efficient (95%)the presence or absence of  cyclodextrin or equimolar quantities
conversion under standard assay conditions was observed (asof various fatty acyl-CoA derivatives and mature SCP-2. Substrates
judged by HPLC analysis). 2-hydroxyoctanoyl-CoA was isolated aswere incubated for 30 min on ice with mature SCP-2 to ensure
previously described for 2-hydroxyphytanoyl-CoA [28]. Retentionfull complex formation. Acyl-CoA esters with side chains up to ten
times were 11.6 and 13.2 min for product and substrate, respec-carbon atoms did not require solubilization with  cyclodextrin or
tively. The sample for ESI MS analysis was repurified using HPLCSCP-2. Determination of kinetic parameters used 10–200 M phyta-
with NH4HCO3 as eluent: The coenzyme A moiety exhibited almostnoyl-CoA (0.56 g PAHX per assay), 20–150 M hexadecanoyl-CoA
identical signals to those reported for isovaleryl-CoA; 1H NMR (500(2.71 g PAHX per assay), or 10–2000 M isovaleryl-CoA (3.64 g
MHz; D2O) (octanoyl moiety)  0.85 (t, J 6.5 Hz, 3H, Me); 1.35–1.40,PAHX per assay). Kinetic parameters were determined by direct
1.50–1.60, 1.65–1.80 (m, 7H, 3  CH2; 1 of CH2CHOH); 2.15–2.20 (m,fitting to a rectangular hyperbola after initial Lineweaver-Burke anal-
1H, 1 of CH2CHOH); 4.2 (b tr, 1H, CHOHCOS). A COSY 1H NMRysis. Values are reported standard error, with Kcat calculated using
spectrum was consistent with the assigned structure; m/z (-ve ESIa mass for PAHX as determined by ESI MS (35,452  3 Da).
MS)  909.42  0.2 (M); calc. 909.7 (M).
Incubations with hexadecanoyl-CoA (1.2 mg) were carried out
Product Characterization in the presence of  cyclodextrin. An efficient (95%) conversion
Incubations of substrates with PAHX (50 reactions, each containing under standard conditions was observed (as judged by HPLC analy-
20 g enzyme) were as previously described [4, 28]. NMR assign- ses). 2-hydroxyhexadecanoyl-CoA was isolated as previously de-
ments are using the previously reported numbering system [28]. scribed for 2-hydroxyphytanoyl-CoA [28]. Retention times were 17.4
Assignments used: s, singlet; d, doublet; t, triplet; m, multiplet; br, and 19.6 min for product and substrate, respectively. The sample
broad; and Me, methyl (for Supplemental Data, please contact the for ESI MS analysis was repurified using NH4HCO3 as eluent. The
Chemistry & Biology Production Department at chembiol@cell.com). coenzyme A moiety exhibited almost identical signals to those re-
The phytanoyl-CoA (1) substrate was HPLC purified as previously ported for phytanoyl-CoA: 1H NMR (500 MHz; D2O: CD3CN, 2:1 [v/
described [28]: 1H NMR (500 MHz; D2O: CD3CN, 2:1 [v/v]) (coenzyme v]) (hexadecanoyl moiety)  0.85 (t, J  6.5 Hz, 3H, Me); 1.10–1.30,
A moiety)  0.75 (s, 3H, 2		-Me); 0.90 (s, 3H, 2		-Me); 2.41 (m, 2H, 1.30–1.45, 1.50–1.60, 1.65–1.80 (m, 26H, 13 x CH2); 4.20 (br t, 1H,
2			-CH2); 2.90–2.95 (m, 2H, 2				-CH2); 3.30 (m, 2H, 1				-CH2); 3.40 CHOHCOS). A COSY 1H NMR spectrum was consistent with the
(m, 2H, 1			-CH2); 3.54 (m, 1H, 1		-CH2); 3.85 (m, 1H, 1		-CH2); 4.02 assigned structure; m/z (-ve ESI MS)  1021.57  0.23 (M); calc.
(1H, s, 3		-CH); 4.24 (br s, 2H, 5	-CH); 4.55 (s, 1H, 4	-CH); 4.82 (2H, 1021.9 (M).
m, 2	-CH and 3	-CH); 6.12 (d, J  7 Hz, 1H, 1	-CH); 8.23 (s, 1H, Incubations with heptadecanoyl-CoA (1.2 mg) were carried out
8-CH); 8.52 (br s, 1H, 2-CH); (phytanoyl moiety) 0.85–0.95 (m, 15H, in the presence of  cyclodextrin. A95% conversion was observed
5  Me); 1.00–1.40 (m, 20H, 9  CH2, 2  MeCH); 1.55 (m, 1H, (as judged by HPLC). 2-hydroxyheptadecanoyl-CoA was isolated
CH(Me)2); 1.95 (m, 1H, CHCH2COS-); 2.41 (m, 1H, 1 of CH2COS-); as previously described for 2-hydroxyphytanoyl-CoA [28]. Retention
2.58 (m, 1H, 1 of CH2COS-). A COSY 1H NMR spectrum was consis- times were 18.8 and 20.4 min for product and substrate, respec-
tent with the assigned structure; m/z (-ve ESI MS)  1061.45  0.20 tively. The sample for ESI MS analysis was repurified using HPLC
(M); calc. 1061.40 (M). with NH4HCO3 as eluent: m/z (-ve ESI MS)  1035.40  0.20 (M);
Incubations with phytanoyl-CoA (Figure 6; 1) (1.2 mg) were car- calc. 1036.0 (M).
ried out in the presence of  cyclodextrin. An efficient (95%) con- Incubations with octadecanoyl-CoA (1.2 mg) were carried out
version under standard conditions was observed (as judged by in the presence of  cyclodextrin. A95% conversion was observed
HPLC analyses). 2-hydroxyphytanoyl-CoA was isolated as pre- (as judged by HPLC). 2-hydroxyoctadecanoyl-CoA was isolated as
viously described [28, 61]. Retention times were 16.0 and 18.0 min previously described for 2-hydroxyphytanoyl-CoA [28]. The reten-
for product and substrate, respectively. The sample for ESI MS tion time was 19.2 min for the product. The sample for ESI MS
analysis was repurified using NH4HCO3 as eluent: 1H NMR (500 MHz; analysis was repurified using HPLC with NH4HCO3 as eluent. The
D2O: CD3CN, 2:1 [v/v]) (coenzyme A moiety)  0.75 (s, 3H, 2		-Me); coenzyme A moiety exhibited almost identical signals to those re-
0.7–0.9 (m, 3H, 2		-Me) 2.35 (br s, 2H, 2			-CH2); 2.8–2.95 (m, 2H, ported for phytanoyl-CoA: 1H NMR (500 MHz; D2O: CD3CN, 2:1 [v/v])
2				-CH2); 3.20 (br s, 2H, 1				-CH2); 3.35 (m, 2H, 1			-CH2); 3.45–3.55 (octadecanoyl moiety)  0.85 (br t, 3H, Me); 1.00–1.20, 1.40–1.50,
(m, 1H, 1		-CH2); 3.55–3.65 (m, 1H, 1		-CH2); 3.80 (br s, 1H, 3		-CH); 1.50–1.60 (m, 30H, 15  CH2); 4.20 (br t, J  7.0 Hz, 1H, CHOHCOS).
4.15 (br s, 2H, 5	-CH); 4.45 (s, 1H, 4	-CH); 6.0 (s, 1H, 1	-CH); 8.2 (s, A COSY 1H NMR spectrum was consistent with the assigned struc-
1H, 8-CH); 8.55 (br s, 1H, 2-CH); (phytanoyl moiety)  0.7–0.85 (m, ture; m/z (-ve ESI MS)  1049.49  0.14 (M); calc. 1050.0 (M).
15H, 5  Me); 0.95–1.4 (m, 20H, 9  CH2, 2  MeCH-); 1.4–1.5 (m, Incubations with arachidoyl-CoA (C-20) (1.2 mg) were carried
1H, CHCOHCOS-) 3.95 (1H, br t, J  7 Hz, CHOH). A COSY 1H NMR out in the presence of  cyclodextrin. A 95% conversion was
spectrum was consistent with the assigned structure; (-ve ESI MS) observed (as judged by HPLC). 2-hydroxyarachidoyl-CoA was iso-
1077.62  0.20 (M); calc. 1077.1 (M). lated as previously described for 2-hydroxyphytanoyl-CoA [28]. Re-
tention times were 20.4 and 21.4 min for product and substrate,Incubations with isovaleryl-CoA (1.2 mg) were carried out in the
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respectively. The sample for ESI MS analysis was repurified using dation of 3-methyl-branched fatty acids. FEBS Lett. 407,
197–200.HPLC with NH4HCO3 as eluent: m/z (-ve ESI MS)  1077.59  0.25
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